Research programme: serotonin 2C receptor agonists - Vernalis/RocheAlternative Names: VER 3323; VER 5384; VER 5593
Latest Information Update: 16 Aug 2010
At a glance
- Originator Vernalis
- Mechanism of Action Serotonin 2C receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 03 Dec 2003 Roche has selected a development candidate from the research programme for obesity for preclinical studies
- 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
- 27 Jun 2003 Vernalis plans to select a new development candidate